Ensysce shareholders approve share issuance to investor and incentive plan increase

Ensysce Biosciences, Inc.

Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.
Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 121,457 to 721,457.
Class I directors William Chang and Lee Rauch reelected; Chang: 518,597 for, Rauch: 516,907 for.
Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.